660MO A phase I, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: The REGOMA-2 trial.
Saved in:
| Title: | 660MO A phase I, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDH wildtype glioblastoma: The REGOMA-2 trial. |
|---|---|
| Authors: | Padovan, M.1 (AUTHOR), Simonelli, M.2 (AUTHOR), De Nicolò, A.3 (AUTHOR), Del Bianco, P.4 (AUTHOR), Cerretti, G.1 (AUTHOR), Caccese, M.1 (AUTHOR), Persico, P.2 (AUTHOR), Menegatti, G.3 (AUTHOR), Bosio, A.1 (AUTHOR), Dipasquale, A.2 (AUTHOR), Maccari, M.1 (AUTHOR), Losurdo, A.2 (AUTHOR), Coppola, M.5 (AUTHOR), Krengli, M.6 (AUTHOR), Lonardi, S.1 (AUTHOR), D'Avolio, A.3 (AUTHOR), De Salvo, G.4 (AUTHOR), Lombardi, G.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS482-S482. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.1235 |
